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SUMMARY
Sensing of cytoplasmic DNA by cyclic guano-
sine monophosphate-adenosine monophosphate
(cGAMP) synthase (cGAS) results in production of
the dinucleotide cGAMP and consecutive activation
of stimulator of interferon genes (STING) followed by
production of type I interferon (IFN). Although cancer
cells contain supra-normal concentrations of cyto-
plasmicDNA, they rarelyproduce type I IFNspontane-
ously. This suggests that defects in the DNA-sensing
pathway may serve as an immune escape mecha-
nism. We find that cancer cells produce cGAMP
that is transferred via gap junctions to tumor-associ-
ated dendritic cells (DCs) and macrophages, which
respond by producing type I IFN in situ. Cancer-cell-
intrinsic expression of cGAS, but not STING, pro-
motes infiltration by effector CD8+ T cells and conse-
quently results in prolonged survival. Furthermore,
cGAS-expressing cancers respond better to geno-
toxic treatments and immunotherapy. Thus, cancer-
cell-derived cGAMP is crucial to protective anti-tumor
CD8+ T cell immunity. Consequently, cancer-cell-
intrinsic expression of cGAS determines tumor immu-
nogenicity and makes tumors hot. These findings
are relevant for genotoxic and immune therapies for
cancer.
INTRODUCTION
Cancer develops in the face of immune surveillance and thus
needs to evade immune control to progress. The tumor microen-
vironment (TME) influences not only tumor progression but also
the response to immune and standard therapies (Binnewies
et al., 2018). Immunogenic or hot tumors contain more infiltrating
T cells than cold tumors and are associated with favorable prog-
nosis and better response to immune checkpoint inhibition (Ga-
lon et al., 2006; Van Allen et al., 2015). In contrast, cold tumors
can be T cell excluded or T cell ignorant (Chen and Mellman,
2017; van der Woude et al., 2017), suggesting that multiple
mechanisms may contribute to a tumor being cold. Besides
the presence of infiltrating T cells, hot tumors are characterized
by a type I interferon (IFN) signature (Gajewski et al., 2013).
Indeed, type I IFN is essential for the generation of protective
anti-tumor immunity, and tumor-infiltrating dendritic cells (DCs)
are essential for both production of and response to type I IFN
in the TME (Diamond et al., 2011; Fuertes et al., 2011; Dai
et al., 2017; Dunn et al., 2006).
The production of type I IFN is downstream of the sensing
of cytoplasmic double-stranded DNA (dsDNA) (Stetson and
Medzhitov, 2006; Vanpouille-Box et al., 2018), which is normally
absent from eukaryotic cells. However, substantial amounts of
cytoplasmic dsDNA are found under pathological conditions,
including viral infection, genomic instability, and DNA damage
(Fenech et al., 2011; Harding et al., 2017; Ishikawa et al., 2009;
Li andChen, 2018;Mackenzie et al., 2017). Consistent with these
findings, radiotherapy (Burnette et al., 2011; Deng et al., 2014)
and chemotherapy (Ahn et al., 2014; Sistigu et al., 2014) induce
type I IFN. Upon binding of dsDNA, cyclic guanosine monophos-
phate-adenosine monophosphate (cGAMP) synthase (cGAS)
catalyzes the formation of the second messenger cGAMP. Sub-
sequently, cGAMP binds to stimulator of interferon genes
(STING), resulting in phosphorylation of interferon regulatory fac-
tor 3 (IRF3) and production of type I IFN (Ablasser et al., 2013a;
Ishikawa and Barber, 2008; Li and Chen, 2018; Sun et al.,
2013; Wu et al., 2013; Gao et al., 2013; recently reviewed in
Ablasser and Chen, 2019).
Cancer cells often constitutively contain a high concentration
of cytoplasmic dsDNA, which further increases upon DNA-
damaging therapies such as radio- or chemotherapy (Shen
et al., 2015). Given the important role of type I IFN in priming of
protective T cell immunity (Diamond et al., 2011; Dunn et al.,
2006; Fuertes et al., 2011), the presence of cytoplasmic dsDNA
in cancer cells may contribute to their immunogenicity. Downre-
gulation of the cGAS/STING pathway correlates with poor prog-
nosis in human cancer (Song et al., 2017; Xia et al., 2016; Yang
et al., 2017). Together, this suggests that the absence of cyto-
plasmic dsDNA sensing contributes to immune evasion of can-
cer cells.
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It was proposed recently that cancer-cell-derived cytoplasmic
dsDNA is transferred to tumor-associated DCs, resulting in
cGAS/STING-dependent production of type I IFN by these
DCs, priming of protective CD8+ T cells, and tumor control
(Woo et al., 2014). How cytoplasmic dsDNA is transferred from
cancer cells to DCs, however, is largely unclear, although trans-
fer via exosomes has been suggested (Kitai et al., 2017). In viral
infections and carcinoma-astrocyte interactions, it was shown
that cGAMP is transferred to neighboring cells via gap junctions,
resulting in the activation of STING in cGAMP-receiving cells
(Ablasser et al., 2013b; Chen et al., 2016).
Inspired by these observations, we proposed that cGAMP
instead of cytoplasmic dsDNA is transferred from cancer cells
to DCs, thus enabling the production of type I IFN and priming
of protective immunity, even in situations where cancer cells
have a compromised STING pathway. We show here that
CD8+ T-cell-mediated control of cancer depends on cancer-
cell-derived cGAMP. This is in line with the recent observation
that natural killer (NK)-cell-mediated control of tumor cells re-
quires expression of STING by host cells and cGAS by cancer
cells (Marcus et al., 2018), thus supporting our hypothesis.
Furthermore, we show that cancer-cell-intrinsic cGASmakes tu-
mors more sensitive to chemo-, radio-, and immunotherapy.
Thus, we propose that expression of cGAS by cancer cells de-
termines tumor immunogenicity as well as its response to geno-
toxic and immune checkpoint inhibition therapies.
RESULTS
Production of Type I IFN in Co-cultures of DCs and
Cancer Cells Requires Expression of cGAS by Cancer
Cells and STING by DCs
To select an experimental system for testing whether cancer-
cell-intrinsic cGAS expression contributes to tumor immunoge-
nicity, we probed the cGAS/STING pathway in different murine
tumor cell lines. Most cell lines expressed cGAS and/or STING,
albeit different amounts (Figures 1A and S1A). To measure
whether the cGAS/STING pathway is functional, we transfected
the cell lines with DNA and quantified secreted type I IFN using a
reporter cell line. All but two cell lines spontaneously produced
very low amounts of type I IFN, which increased upon transfec-
tion with DNA (Figure 1B). In the CT26 cell line that is considered
immunogenic, we next established CT26 mutants deficient for
cGAS (CT26DMb21d1) or STING (CT26DTmem173) using CRISPR/
Cas9 technology and validated the absence of cGAS or STING
by western blot (Figure 1C). CT26 cells modified with an empty
vector (CT26ctrl) were used as control. In addition, we engineered
cGAS-negative Lewis lung carcinoma (LLC; ATCC CRL-1642)
cells (Figure 1A) to express cGAS (LLCMb21d1) and confirmed
the expression of cGAS by western blot (Figure 1D).
As the STING pathway is frequently compromised in cancer
cells (Song et al., 2017; Xia et al., 2016; Yang et al., 2017), they
rely on other cell types for the production of immune-stimulating
type I IFN. It has been suggested that tumor-associated DCs
fulfill this role after uptake of cancer-cell-derived dsDNA (Klar-
quist et al., 2014; Woo et al., 2014). To study whether cancer
cells can induce the production of type I IFN in DCs, we
measured the amount of type I IFN in co-cultures (Figures
1E–1G and S1B–S1D). We observed a strong induction of type
I IFN in co-cultures of CT26ctrl cells with wild-type bone-
marrow-derived DCs (BMDCs) compared to cancer cells or
BMDCs alone (Figures 1F and S1B). Type I IFN was absent
from co-cultures of cGAS-deficient CT26DMb21d1 cells with
wild-type BMDCs (Figure 1F) but present in co-cultures of
STING-deficient CT26DTmem173 cells with BMDCs (Figure S1C).
These data suggest that the production of type I IFN depends
on cancer-cell-intrinsic expression of cGAS, but not STING.
Co-cultures using cGAS-deficient BMDCs gave similar results
to those using wild-type BMDCs, suggesting that expression
of cGAS in BMDCs is dispensable for the production of type I
IFN. Type I IFN was not detectable in co-cultures of any CT26
cell line with STING-deficient BMDCs (Figure 1F). This suggests
that expression of STING in DCs is essential for the production
type I IFN in co-cultures cGAS-expressing cancer cells. In line
with the abovementioned findings, we observed that cGAS-
overexpressing LLCMb21d1 cells induce type I IFN secretion in
co-cultured BMDCs, while the parental LLC cells do not
(Figure 1G).
Intercellular transfer of cGAMP has been reported to depend
on gap junctions (Ablasser et al., 2013b; Chen et al., 2016). To
investigate whether cell-cell contact is indeed required for
cGAMP transfer from cancer cells to DCs, we used a transwell
system and found that the production of type I IFN was abro-
gated (Figure S1D). This excludes transfer of soluble or exo-
some-associated cGAMP.
To identify whether cGAMP is transferred from tumor cells to
DCs over gap junctions, we generated connexin-43 (CX43)-defi-
cient CT26 cells (CT26DGja1) (Figure 1C). To assess the exchange
of cytoplasm between cells, we used the calcein AM transfer
assay (Figure S1E) (Ablasser et al., 2013b; Saccheri et al.,
2010). CT26DGja1 cells transferred significantly less calcein AM
to co-cultured BMDCs than CT26ctrl cells (Figures S1F and
S1G), suggesting that deleting Gja1 is sufficient to reduce cyto-
plasmic exchange. We then co-cultured CX43-deficient CT26-
DGja1 cells with BMDCs and found that the production of type
IFN I was abolished (Figure 1F).
Thus, we showed that minimal requirements for production of
type I IFN in cancer cell/BMDC co-cultures are the expression of
cGAS in cancer cells and STING in BMDCs, suggesting transfer
of cGAMP and not dsDNA from cancer cells to BMDCs. Further-
more, we showed that cGAMP is transferred via gap junctions
in vitro.
Cancer-Cell-Intrinsic cGAS Deficiency Promotes Tumor
Progression and Makes Tumors Cold
After having established that cancer-cell-intrinsic cGAS is
essential for production of type I IFN by neighboring DCs
in vitro, we investigated the contribution of cancer-cell-derived
cGAMP on immune surveillance. Therefore, we injected CT26ctrl,
CT26DMb21d1, or CT26DTmem173 cells subcutaneously (s.c.) in
BALB/c mice and monitored tumor growth and survival (Fig-
ure 2A). We found that cGAS-deficient, but not STING-deficient,
CT26 tumors grow faster than control CT26 tumors (Figure 2B),
resulting in significantly reduced survival (Figure 2C).
To exclude that the increased tumor growth of CT26DMb21d1
cells is due to cell-intrinsic features, we measured the growth
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of CT26ctrl, CT26DMb21d1, or CT26DTmem173 cancer cells in vitro
and found no significant difference (Figure S2A). Next, we in-
jected CT26ctrl, CT26DMb21d1, or CT26DTmem173 cells in
NOD.Cg-Prkdcscid Il2rgtm1Wjl (NSG) mice that lack T, B, and NK
cells (Figure S2B). All three CT26 cell lines showed similar growth
and survival characteristics (Figures S2C and S2D), suggesting
that the increased growth of cGAS-deficient CT26 tumors is
due to compromised immune surveillance.
To further support the role of cancer-cell-derived cGAMP in
immune control of tumors, we analyzed the immune infiltrates
associated with CT26ctrl, CT26DMb21d1, and CT26DTmem173 tu-
mors in BALB/c mice 22 d after tumor cell injection (Figure 2D).
Within the CD45+ leukocyte population, the proportions of
CD3+, CD8+, and CD8+ IFN-g+ T cells were significantly lower
in cGAS-deficient tumors than control or STING-deficient tumors
(Figures 2E and S2E). To address whether the tumor-specific
CD8+ T cell population is influenced by the absence of cGAS in
cancer cells, we analyzed IFN-g production by tumor-associated
CD8+ T cells after in vitro stimulation with a cancer-cell-specific
peptide, AH-1 (Huang et al., 1996) (Figure 2F, left panel, and Fig-
ure S2F). In addition, we saw that cGAS-expressing tumors
contained a higher proportion of CD39+ cells within the CD8+
population (Figure 2F, right panel, and Figure S2F), suggesting
an increase in tumor-specific CD8+ T cells (Simoni et al., 2018).
Our observation that cGAS-proficient tumors contain higher
concentrations of the T-cell-derived effector cytokines IFN-g
and tumor necrosis factor alpha (TNF-a) further substantiates
that cGAS-expressing tumors are hot (Figure 2G). The proportion
of other immune cells like CD4+ and FoxP3+ CD4+ T cells as
well as myeloid cells were comparable in the different tumors
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Figure 1. Production of Type I IFN in Co-cultures of DCs and Cancer Cells Requires Expression of cGAS by Cancer Cells and STING by DCs
(A) Expression of cGAS and STING protein in murine tumor cell lines in vitro. Expression was measured by western blot, and data are represented as relative
protein expression in arbitrary units (cGAS/b-actin and STING/a-tubulin). The heatmap shows the range between low (white) to high (black) expression. Plots
show pooled results from three independent experiments.
(B) In vitro production of type I IFN by murine tumor cell lines over 24 h. The upper row shows spontaneous production, and the lower row shows production of
cells transfected with 1 mg genomic dsDNA. The heatmap shows the range between 0 pg/mL (white) and 1,000 pg/mL (black). Plots show pooled results from
three independent experiments.
(C) Confirmation of deficiency of cGAS, STING, and connexin-43 (CX43) by western blot in CT26DMb21d1, CT26DTmem173, and CT26DGja1 cells, respectively.
(D) Confirmation of cGAS overexpression in LLCMb21d1 by western blot.
(E) Experimental design for (F) and (G). Cancer cells (0.15 x 106) were co-cultured with 0.5 3 106 bone marrow derived dendritic cells (BMDCs) from wild-type
(WT), cGAS-deficient (Mb21d1) or STING-deficient (Tmem173) mice. After 24 h, type I IFNwasmeasured in the supernatant with the reporter cell line LL171. Every
symbol represents one biological replicate. Bars represent mean ± SD. Results are representative of 2 independent experiments each.
(F) CT26ctrl, CT26DMb21d1, and CT26DGja1 cancer cells.
(G) LLC and LLCMb21d1 cancer cells.
See also Figure S1.
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Figure 2. Cancer-Cell-Intrinsic cGAS Expression Makes Tumors Hot and Promotes Immune Surveillance
(A) Experimental design for (B) and (C). CT26ctrl, CT26DMb21d1, or CT26DTmem173 cells were injected subcutaneously into BALB/c mice (n = 10 mice per group).
(B) Tumor size was measured with a caliper. Every line represents an individual mouse. Results are representative of four independent experiments.
(C) Survival curve. Death event is defined as tumor size >225 mm2. Statistics were calculated using the log-rank (Mantel-Cox) test. Results are representative of
four independent experiments. **p < 0.01.
(D) Experimental design for (E)–(G). CT26ctrl, CT26DMb21d1, or CT26DTmem173 cells were injected subcutaneously into BALB/c mice (n = 9–10 mice per group).
(E) Percentage of immune cells in tumors analyzed by flow cytometry at the endpoint (day 22). Percentage of IFN-g+ CD8+ T cells in tumors was determined after
in vitro stimulation with phorbol 12-myristate 13-acetate (PMA)/ionomycin in the presence of brefeldin A. Every symbol represents an individual mouse. Bars
represent mean ± SD. Statistics were calculated using one-way ANOVA with Tukey’s multiple comparison correction. Gating strategies are shown in Figure S2E.
Results are representative of three independent experiments.
(legend continued on next page)
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(Figure S2G; data not shown). Moreover, we found no differ-
ences in the proportion of NK cells in the different tumors
(Figure S2H). For gating strategies, see Figures S2I and S2J,
respectively.
Depletion of CD8+ T cells promoted the growth of CT26ctrl, but
not CT26DMb21d1, tumors (Figure S2K). This underscores the
relevance of CD8+ T cells for controlling CT26 tumor growth as
well as the importance of cancer-cell-intrinsic cGAS for recruit-
ing those T cells (Figure 2E).
To substantiate our findings, we monitored tumor growth and
survival of C57BL/6 mice that were injected with LLC or
LLCMb21d1 cells (Figure S3A). We found that the overexpression
of cGAS in LLC cells resulted in slower tumor growth (Fig-
ure S3B), prolonged survival (Figure S3C), and an infiltrate remi-
niscent of hot tumors (Figures S3D and S3E). To strengthen the
concept that type I production in the TME depends on the trans-
fer of cGAMP, but not DNA, from cancer to host cells, we in-
jected LLC or LLCMb21d1 in wild-type C57BL/6 or cGAS-deficient
B6(C)-Cgastm1d(EUCOMM)Hmgu/J (cGAS/ B6) mice (Figure S3F).
As shown above, LLCMb21d1 tumors contained more effector
CD8+ T cells than LLC tumors, independently of the mouse ge-
notype (Figures S3G and S3H). These data suggest that the
DNA-sensing capacity of the host is insignificant for the genera-
tion of antitumor immunity.
Thus, cancer-cell-intrinsic cGAS expression promotes infiltra-
tion by effector CD8+ T cells that control tumor growth.
Cancer-Cell-Derived cGAMP Induces Production of
Type I IFN by Tumor-Associated DCs
Using co-cultures of cancer cells and BMDCs, we showed that
cancer-cell-derived cGAMP is transferred to DCs, which pro-
duce type I IFN in turn. To investigate whether this process is
operative in tumors in vivo, we isolated established CT26ctrl
and CT26DMb21d1 tumors from BALB/c mice (Figure 3A). From
half of the tumors, we prepared a lysate; the other half was pro-
cessed for single-cell analysis by flow cytometry. The lysate of
cGAS-deficient CT26 tumors contained significantly less IFN-b
than that of control CT26 tumors (Figure 3B). To identify the
cell type that produces type I IFN in CT26 tumors, which we
consider a proxy for uptake of cancer-cell-derived cGAMP, we
used PrimeFlow. We applied this flow-cytometry-based method
to detect transcripts in single cells, because intracellular staining
for type I IFN using antibodies is not sufficiently sensitive or reli-
able (Lienenklaus et al., 2009; Scheu et al., 2008). We stained
CT26ctrl and CT26DMb21d1 tumors for different lineage markers
as well as Ifnb1 transcripts. We detected the Ifnb1 signal almost
exclusively in theCD45+ leukocyte fraction (Figure 3C).We found
a significantly higher percentage of Ifnb1+ cells within the
leukocyte fraction of CT26ctrl tumors than in cGAS-deficient
CT26DMb21d1 tumors (Figure 3D). Moreover, the majority of
Ifnb1+ cells in CT26ctrl tumors were DCs and macrophages, of
which bothwere reduced in cGAS-deficient CT26DMb21d1 tumors
(Figures 3E and S4A). Conventional DC1s (cDC1s) and cDC2s
differ concerning their capacity to activate T cells and can be
discriminated by surface expression of CD11b or CD103 (Broz
et al., 2014). We saw that both cDC1s and cDC2s expressed
significantly higher amounts of Ifnb1 transcripts in CT26ctrl tu-
mors than in cGAS-deficient CT26DMb21d1 tumors (Figures S4B
and S4C). Comparison of the Ifnb1 signal in tumor-associated,
major histocompatibility complex class II (MHCII)+ cells to that
in MHCII+ naive spleen cells (negative control) or MHCII+ spleen
cells stimulated in vitro with a STING agonist (positive control)
technically validated this readout (Figure S4D).
Thus, DCs and macrophages associated with cGAS-express-
ing tumors produce type I IFN in situ, whereas their ability to do
so is compromised in cGAS-deficient tumors. This suggests that
cancer-cell-derived cGAMP indeed is transferred to neighboring
myeloid cells.
The Efficacy of DNA-Damaging Cancer Therapies
Depends on Cancer-Cell-Intrinsic Expression of cGAS
In response to DNA damage, genomic instability, or viral
infection, the amount of cytoplasmic dsDNA is increased in
eukaryotic cells (Fenech et al., 2011; Harding et al., 2017; Ishi-
kawa et al., 2009; Mackenzie et al., 2017). Since cytoplasmic
dsDNA is the substrate for cGAS, we investigated the effect of
genotoxic treatments on immune-mediated control of cGAS-
deficient and control CT26 tumors. First, we confirmed that
the amount of cytoplasmic dsDNA in untreated CT26 cancer
cells is indeed higher compared to untransformed cells by
100-fold (Figure S5A). We then applied genotoxic stress to
CT26 cells in vitro to validate an increase of the cytoplasmic
dsDNA concentration. Different genotoxic treatments including
radiation with 8 Gy or 20 Gy as well as exposure to 15 mM
cisplatin increased the amount of cytoplasmic DNA significantly
(Figure S5A).
Second, we investigated whether cGAS-deficient cancer cells
have a decreased sensitivity to genotoxic treatments per se and
determined the survival of CT26ctrl or CT26DMb21d1 cancer cells
after treatment with radiation or cisplatin (Figure S5B). We found
that both cell lines showed a similar decrease in the surviving
fraction upon increasing doses of radiotherapy and cisplatin
(Figure S5B). In addition, we observed similar radiation-induced
DNA damage in CT26ctrl or CT26DMb21d1 cells as measured by
gamma-H2AX staining (Figure S5C and S5D). This suggests
that the sensitivity toward genotoxic treatments is not influenced
by the absence of cGAS in CT26 cancer cells.
Third, we analyzed the immune-stimulating effect of radio-
therapy in mice bearing cGAS-deficient or control CT26 tumors.
Therefore, we subjected BALB/c mice bearing established
(F) Percentage of IFN-g+ (left panel) and CD39+ (right panel) cells within the CD8+ T cell population in the tumor analyzed by flow cytometry at the endpoint (day 17)
after in vitro stimulation with AH-1 peptide in the presence of brefeldin A. Every symbol represents an individual mouse. Bars representmean ±SD. Statistics were
calculated using the Mann-Whitney U test. Gating strategies are shown in Figure S2F. Results are representative of two independent experiments.
(G) Concentration of IFN-g and TNF-a in tumor lysate normalized to total protein concentration measured at the endpoint (day 22). Every symbol represents an
individual mouse. Bars represent mean ±SD. Statistics were calculated using unpaired two-tailed Student’s t test. *p < 0.05, **p < 0.01. Results are representative
of two independent experiments.
See also Figures S2 and S3.
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CT26ctrl or CT26DMb21d1 tumors to radiotherapy given as a single
dose of 20 Gy (Surace et al., 2015) (Figure 4A). As shown above,
untreated CT26DMb21d1 tumors grew faster than untreated
CT26ctrl tumors (Figure 4B), which resulted in a shorter survival
(Figure 4C). Although both tumors responded to radiotherapy,
therapy-induced growth retardation and increase in survival
was only marginal in mice bearing cGAS-deficient tumors. In
contrast, the clinical response of mice bearing CT26ctrl tumors
was very pronounced and resulted in tumor clearance in 3 out
of 10 mice (Figures 4B and 4C). Radiotherapy supports CD8+
T-cell-mediated immunity (Gupta et al., 2012; Surace et al.,
2015; Galluzzi et al., 2017); therefore, we characterized immune
infiltrates in irradiated and untreated tumors. We found that
numbers of CD3+ and CD8+ T cells were increased upon radio-
therapy in CT26ctrl tumors, but not cGAS-deficient CT26DMb21d1
tumors (Figure S5E).
We used a similar experimental setup to compare the sensi-
tivity of CT26ctrl or CT26DMb21d1 tumors to another genotoxic
treatment, cisplatin (Figure 4D). Cisplatin significantly retarded
tumor growth and prolonged survival of mice bearing CT26ctrl tu-
mors (Figures 4E and 4F). In contrast, cisplatin had no effect on
the growth of cGAS-deficient CT26DMb21d1 tumors (Figure 4E),
nor did it increase survival (Figure 4F).
Thus, although radiotherapy and cisplatin have a different
mode of action, both induce higher concentrations of cyto-
plasmic dsDNA. This explains why both genotoxic therapies
show only limited or even no clinical efficacy when tumors lack
the expression of cGAS and consequently cannot process the
dsDNA into immune-stimulating cGAMP.
cGAS-Expressing Tumors Respond Better to Immune
Checkpoint Inhibition
Several reports described that hot tumors respond better to im-
mune checkpoint inhibition (Ayers et al., 2017; Van Allen et al.,
2015). Since cGAS-expressing tumors have a hot phenotype,
we hypothesized that treatment with anti-PD1 plus anti-CTLA4
is more efficacious in such tumors. To test this, we treated
mice bearing CT26ctrl or CT26DMb21d1 tumors with anti-PD1
plus anti-CTLA monoclonal antibodies and monitored tumor
growth and survival (Figure 5A). As shown in Figures 2 and 4, un-
treated CT26DMb21d1 tumors grew faster than untreated CT26ctrl
tumors, which resulted in a shorter survival (Figures 5B and 5D).
Although both tumors responded to the checkpoint inhibitor
treatment, CT26ctrl tumors responded significantly better than
cGAS-deficient CT26DMb21d1 concerning the survival of these
mice (Figure 5D). We observed complete tumor rejection in 8
out of 20 mice with CT26ctrl tumors but only 2 out of 20 mice
with CT26DMb21d1 tumors (Figure 5C).
Cancer-Cell-Intrinsic Expression of cGAS Correlates
with Infiltration of CD8+ T Cells in HumanMicrosatellite-
Stable Colorectal Cancer
To determine the clinical relevance of our findings, we analyzed
colorectal adenocarcinoma resection specimens from 25
A B C
D E
Figure 3. Cancer-Cell-Derived cGAMP Induces the Production of IFN-b by Tumor-Associated DCs
(A) Experimental design. CT26ctrl or CT26DMb21d1 cells were injected subcutaneously into BALB/c mice (n = 10 mice per group).
(B) IFN-b concentration in tumor lysate normalized to total protein concentrationmeasured at the endpoint (day 14). Every symbol represents an individual mouse.
(C) Representative plots for measurement of Ifnb1mRNA by flow cytometry in CT26ctrl and CT26DMb21d1 tumors. The upper panels are gated on live, CD45 cells.
The lower panels are gated on live, single CD45+ cells.
(D) Percentage of Ifnb1+ cells in the CD45+ population at the endpoint (d 14).
(E) Percentage of DCs andmacrophages of all live, single Ifnb1+ cells. DCswere gated as CD45+CD11c+MHCII+ andmacrophages as CD45+CD11b+F4/80+ cells.
Every symbol represents an individual mouse. Bars represent mean ± SD. Statistics were calculated using unpaired two-tailed Student’s t test. *p < 0.05,
**p < 0.01, ***p < 0.005. Gating strategies are shown in Figure S4A. Results are representative of two independent experiments.
See also Figure S4.
Cell Reports 29, 1236–1248, October 29, 2019 1241
patients. Using four-color multiplex immunofluorescence, we
stained for cGAS, pan-cytokeratin (PanCK; epithelial cells), and
CD8 (CD8+ T cells) (Figure 6A). Our abovementioned data sug-
gest that cancer-cell-intrinsic expression of cGAS characterizes
hot tumors. Therefore, we specifically analyzed cGAS expression
by tumor cells. We first applied an algorithm to segment the tis-
sue in tumor and stroma based on expression of PanCK and
morphology (Figure 6B). We then determined which proportion
of cancer cells expressed cGAS (Figure 6C) and quantified the
number of CD8+ T cells per image (Figure 6D). We found that
only 15 out of 151 tumor images contained >10% cGAS+ cancer
cells (Figure 6E), whereas cGAS expression was detectable in all
patients in the tumor-adjacent non-diseased tissue (Figure S6).
We found a significant correlation between the percentage of
cancer cells that express cGAS and the density of tumor-infil-
trating CD8+ T cells (Figure 6E). In one patient with heteroge-
neous expression of cancer-cell-intrinsic cGAS, we saw that
CD8+ T cells were mainly present in areas with cGAS expression
(Figure 6F). This underscores the concept that cancer-cell-
intrinsic cGAS directly drives the infiltration of CD8+ T cells.
A D
B
E
C F
Figure 4. The Efficacy of DNA-Damaging Cancer Therapies Depends on Cancer-Cell-Intrinsic Expression of cGAS
(A) Experimental design for (B) and (C). CT26ctrl or CT26DMb21d1 cells were injected subcutaneously into BALB/c mice (n = 10 mice per group). Radiotherapy (RT;
13 20 Gy) was applied to the tumor on day 13.
(B) Tumor size was measured with a caliper. Every line represents an individual mouse.
(C)Survival curve.Deathevent isdefinedas tumor size>225mm2.Statisticswere calculatedusing the log-rank (Mantel-Cox) test. **p<0.01, ***p<0.005, ****p<0.001.
(D) Experimental design for (E) and (F). CT26ctrl or CT26DMb21d1 cells were injected subcutaneously into BALB/c mice (n = 10 mice per group). Mice were treated
with cisplatin (3 mg/kg) or saline on days 8 and 13.
(E) Tumor size was measured with a caliper. Every line represents an individual mouse.
(F) Survival curve. Death event is defined as tumor size >225 mm2. Statistics were calculated using the log-rank (Mantel-Cox) test. *p < 0.05, **p < 0.01.
See also Figure S5.
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Thus, also in humans, cancer-cell-intrinsic cGAS expression
positively correlates with T cell infiltration.
DISCUSSION
In this study, we have shown that cGAS expression in cancer
cells is critical for tumor control by CD8+ T cells. Cancer cells
have plenty of substrate for cGAS because of their unusually
high concentration of cytoplasmic dsDNA (Li and Chen, 2018).
Consequently, cancer cells can produce substantial amounts
of cGAMP. We uncovered that in vitro cGAMP is transferred
via gap junctions from cancer cells to DCs, where it induces
the production of type I IFN in a STING-dependent fashion.
This is in line with the observations that intra-tumoral or even
systemic application of STING agonists (Corrales et al., 2015;
Dai et al., 2017; Li et al., 2016; Ramanjulu et al., 2018) or
induction of gap junctions between cancer cells and DCs
(Saccheri et al., 2010) improves immune surveillance. Further-
more, we found that cancer-cell-intrinsic cGAS is critical for
the efficacy of genotoxic treatments such as radio-, chemo-,
and immunotherapy.
Although initially known for antiviral activity, type I IFN influ-
ences immunity via direct action on innate and adaptive lym-
phocytes. For example, type I IFN activates NK cells to
execute potent antiviral (Biron et al., 1999) and anti-tumor de-
fense (Swann et al., 2007). In addition, type I IFN is essential for
rejection of tumors by CD8+ T cells (Diamond et al., 2011;
Dunn et al., 2006; Fuertes et al., 2011). The connection be-
tween type I IFN and the cGAS/STING pathway has been
appreciated for some time (Stetson and Medzhitov, 2006),
and the importance of this pathway for control of cancer
has recently received increasing attention (reviewed in Van-
pouille-Box et al., 2018). According to the current view, can-
cer-cell-derived DNA obtains access to the cytoplasm of
host cells via an unknown mechanism (Woo et al., 2014) or
A B
C
D
Figure 5. cGAS-ExpressingTumorsRespond
Better to Immune Checkpoint Inhibition
(A) Experimental design for (B)–(D). CT26ctrl or
CT26DMb21d1 cells were injected subcutaneously
into BALB/c mice (n = 10 mice per group). On days
7 and 12, mice were injected intraperitoneally (i.p.)
with 250 mg anti-PD1 (RMP1-14) and 250 mg anti-
CTLA4 (9H10) antibodies or PBS.
(B–D) Pooled data from two identical experiments.
(B) Tumor size was measured with a caliper. Every
line represents an individual mouse. (C) Number of
tumor-bearing and tumor-free mice in CT26ctrl or
CT26DMb21d1 after treatment with anti-PD1 and
anti-CTLA4. Bars represent the total number of
mice per group. Statistics were calculated using
the chi-square test. (D) Survival curve. Death event
is defined as tumor size >225 mm2. Statistics were
calculated using the log-rank (Mantel-Cox) test.
*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001.
exosomes (Kitai et al., 2017), resulting
in STING-dependent production of type
I IFN by the latter. This view is chal-
lenged by our results and work recently reported by Marcus
et al. (2018) showing that cGAMP, and not dsDNA, is trans-
ferred from cancer cells to DCs.
The pivotal role of STING-dependent production of type I IFN
by tumor-infiltrating myeloid cells (DCs and macrophages) con-
cerning the generation of protective anti-tumor immunity was
shown in several studies (Corrales et al., 2015; Marcus et al.,
2018;Woo et al., 2014). However, which upstream events induce
STING signaling in tumor-infiltrating DCs was not completely un-
derstood. We identified cancer-cell-derived cGAMP as the
molecule that induces STING-dependent type I IFN production
by DCs and macrophages, suggesting that host cGAS is
dispensable for this response. Indeed, it has been shown in
different tumor models that cGAS deficiency in the host does
not influence tumor growth (Marcus et al., 2018; Wang et al.,
2017). Along these lines, our in vivo data show that the immune
infiltration of tumors from wild-type and cGAS-deficient mice is
comparable for both hot and cold tumors. Additionally, we
confirmed in vitro that the production of type I IFNs required
cGAS expression in cancer cells and STING expression in
DCs. Our data, together with previously published work, indicate
that cGAMP, and not dsDNA, induces STING-activation in
myeloid cells, including DCs and macrophages, and the conse-
quent activation of the adaptive immune system. How cGAMP is
transferred in vivo from cancer to immune cells has not been
determined yet.
We showed that cancer-cell-intrinsic expression of cGAS and
consequent production of cGAMP promotes tumor control by
CD8+ T cells, mainly by driving their differentiation into effectors.
The same mechanism accounts for control of tumors that are
recognized by NK cells rather than CD8+ T cells (Marcus
et al., 2018). Both studies together make a strong cause for
the importance of cancer-cell-intrinsic expression of cGAS in
the defense against cancer by innate as well as adaptive im-
mune cells. Being equally important for innate and adaptive
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immunity against cancer assigns a key role to cGAS among im-
mune regulators.
We showed that cancer-cell-intrinsic expression of cGAS
influences the quality of immune infiltration in human colo-
rectal adenocarcinoma. Since CD8+ T cell infiltration corre-
lates with increased survival of cancer patients in many
disease entities, analysis of cGAS expression by cancer cells
may be a potential biomarker for survival or response to
(immune) therapies. We observed that tumor-adjacent
non-diseased tissues in all patients expressed cGAS in
epithelial and stromal cells, whereas cGAS expression was
rare in carcinoma cells. This suggests that loss of cGAS is
A B C D
E F
Figure 6. Cancer-Cell-Intrinsic Expression of cGAS Correlates with Infiltration of CD8+ T Cells in Human Microsatellite-Stable Colorectal
Cancer
(A) Representative images of four-color multiplex immunofluorescence on resection specimens from four colorectal adenocarcinoma patients. Staining shows
cGAS (green), epithelial cells (PanCK, magenta), CD8+ T cells (CD8, white), and nuclear staining (DAPI, blue). Scale bar represents 100 mm.
(B) Representative images of the applied tissue segmentation algorithm to differentiate tumor (magenta) and stroma (yellow) based on morphology and PanCK
expression.
(C) Representative images of the applied cell segmentation and scoring algorithm in the tumor area for cGAS-positive (red), and -negative (blue).
(D) Representative images of the applied cell segmentation and scoring algorithm in the tumor and stroma for CD8-positive (green) and -negative (blue) cells.
(E) Correlation of the percentage of cGAS+ tumor cells and the percentage of CD8+ T cells per image. Every symbol represents one image; in total, 151 images
were analyzed from 25 patients. At least 6 images were analyzed per patient. Statistics were calculated using nonparametric Spearman correlation.
(F) Correlation of the percentage of cGAS+ tumor cells and the percentage of CD8+ T cells in one patient with a heterogeneous distribution of cGAS expression in
the tumor. Every symbol represents one image; in total, 20 images were analyzed from patient 14. Correlation was calculated using a parametric Pearson test.
Statistics were calculated using the Pearson correlation coefficient.
See also Figure S6.
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an immune escape mechanism and goes in line with the
observation that the loss of cGAS expression correlates with
progression of colorectal cancer (Xia et al., 2016; Yang
et al., 2017).
Although most cancer cells contain a substantial concentra-
tion of cytoplasmic dsDNA, this can further be increased by gen-
otoxic stress (Harding et al., 2017; Ha¨rtlova et al., 2015; Sheng
et al., 2018). This explains why immune stimulation by genotoxic
treatment is cGAS/STING dependent and radiotherapy is less
efficient in STING-deficient mice (Deng et al., 2014). Also,
combining radiotherapy with a STING agonist improved thera-
peutic efficacy (Baird et al., 2016). Moreover, artificially
enhancing the concentration of cytoplasmic DNA and cyclic di-
nucleotides in dying cancer cells enhanced STING signaling in
cells that engulfed such dying cells, promoting immune activa-
tion (Ahn et al., 2018).
A recent report showed that the increase of cytoplasmic
dsDNA upon radiotherapy depends on the dose of radiation
used; doses >10–12 Gy induce expression of the DNA exonu-
clease TREX1, resulting in degradation of cytoplasmic dsDNA
in three different cancer cell lines (TSA, MC38, and 4T1) and
reduced immunogenicity (Vanpouille-Box et al., 2017). In
contrast, we found a comparable increase of cytoplasmic
dsDNA after irradiation with 8 or 20 Gy as well as exposition to
15 mM cisplatin in CT26. We currently lack an explanation for
this discrepancy. Furthermore, we showed that therapeutic effi-
cacy of radiotherapy given as a single dose of 20 Gy was
decreased in cGAS-deficient CT26 tumors when compared to
cGAS-proficient tumors.
We can offer at least two explanations for our observation
that cGAS-expressing cancers respond better to genotoxic
treatment. First, therapy-induced increase of cytoplasmic
dsDNA may translate directly in production of more cGAMP
and type I IFN, thus providing a stronger immune stimulus.
However, untreated cancer cells already contain at least
10-fold more cytoplasmic dsDNA than untransformed cells,
and we do not know whether a further 2- to 4-fold increase
by genotoxic therapy significantly adds to immune stimulation.
Second, genotoxic therapies, and perhaps all therapies that
involve concomitant immune stimulation, may work better
when tumors are hot at the start of therapy. Indeed, some
studies show that immune checkpoint inhibitors work better if
cancer cells contain substantial amounts of cytoplasmic
dsDNA (Vanpouille-Box et al., 2017) or if they are combined
with intratumoral application of STING agonists (Wang et al.,
2017; Ager et al., 2017).
Tumor-infiltrating effector CD8+ T cells mediate the clinical
response to immune checkpoint inhibitors. Therefore, hot tu-
mors respond better to immune checkpoint inhibition (Ayers
et al., 2017; Van Allen et al., 2015). cGAS-expressing tumors
responded significantly better to anti-PD1 and anti-CTLA4
treatment than cGAS-deficient tumors, which is in line with our
observation that cancer-cell-intrinsic cGAS promotes infiltration
by effector CD8+ T cells that can be targeted by immune check-
point inhibition.
Despite the wealth of evidence for cGAS/STING supporting
anti-tumor immunity, there are reports showing a detrimental
role of this pathway. First, STING was shown to promote the
growth of poorly immunogenic tumors via indolamine 2,3 diox-
ygenase (IDO) activation (Lemos et al., 2016). This study used
mostly LLC and EL-4 cancer cells, and we showed here that
LLCs contain low amounts of cGAS, which may explain their
low immunogenicity. The authors did not address, however,
how STING drives IDO production and subsequent suppres-
sion of CD8+ T cells. Second, it was shown that chromosomal
instability leads to micronuclei, increased amounts of cyto-
plasmic dsDNA, activation of the cGAS/STING pathway, and
increased metastasis (Bakhoum et al., 2018). Most of the
experiments used xenografted human cancer cells, thus pre-
cluding involvement of the immune system. Third, STING-defi-
cient mice are resistant to inflammation-driven skin squamous
cell carcinoma (Ahn et al., 2014), which may not be represen-
tative of most cancers. Fourth, metastatic cells in the brain
establish gap junctions with astrocytes to transfer cGAMP.
The resulting, STING-dependent production of pro-inflamma-
tory cytokines supports proliferation of metastasized cells
and makes them chemoresistant (Chen et al., 2016). Thus, in
a particular context, the cGAS/STING pathway may promote
cancer.
In summary, together with the recent report by
Marcus et al. (2018), our results propose that cancer-cell-
intrinsic cGAS is essential to tumor control by innate as
well as adaptive immunity. Thus, cGAS expression makes tu-
mors hot and may serve as a useful biomarker for immunoge-
nicity and presumably also for responsiveness to (immune)
therapy.
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CD3e – APC BioLegend Clone 17A2; 100236; RRID:AB_2561456
FoxP3 – APC eBioscience Clone FJK-16 s; 17-5773-80; RRID:AB_469456
CD8a – APC BioLegend Clone 53-6.7; 100712; RRID:AB_312751
CD4 – APC/Cy7 BioLegend Clone GK1.5; 100414; RRID:AB_312699
CD3e – APC/Cy7 BioLegend Clone 17A2; 100222; RRID:AB_2242784
CD11c – BV650 BioLegend Clone N418; 117339; RRID:AB_2562414
CD45.2 – BV605 BioLegend Clone 104; 109841; RRID:AB_2563485
CD11b – BV510 BioLegend Clone M1/70; 101245; RRID:AB_2561390
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F4/80 – BV421 BioLegend Clone BM8; 123132; RRID:AB_11203717
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Biological Samples
Tissue microarray of 120 colorectal
adenocarcinoma samples
Department of Pathology and
Molecular Pathology, University
Hospital Zurich, Switzerland
N/A
Paraffin sections of colorectal adenocarcinoma
samples with determined MSI status
Triemli Hospital Zurich N/A
Chemicals, Peptides, and Recombinant Proteins
Recombinant mouse IFN-beta Sigma-Aldrich I9032-1VL
Polyethylenimine (PEI) Polysciences 23966-1
Cisplatin Sandoz L01XA01
Matrigel Corning 354234
Zombie-Violet fixable viability stain BioLegend 423114
Zombie-NIR fixable viability stain BioLegend 423106
PMA Sigma P1585-1MG
Ionomycin Sigma I0634-1MG
Brefeldin A Sigma B6542-25MG
AH-1 peptide (SPSYVYHQF) PolyPeptide Laboratories N/A
FoxP3/Transcription factor staining buffer set eBioscience 00-5523-00
Opal 520 PerkinElmer FP1487001KT
Opal 540 PerkinElmer FP1494001KT
Opal 620 PerkinElmer FP1495001KT
Opal 650 PerkinElmer FP1496001KT
Opal 690 PerkinElmer FP1497001KT
1X Plus Amplification Diluent PerkinElmer FP1498
Anti-PD1 Hideo Yagita, Tokyo, Japan RMP1-14
Anti-CTLA4 Jim Allison, Texas, US 9H10
Calcein, AM, cell-permanent dye Invitrogen C3100MP
Poly-L-lysine (0.1%) Sigma Aldrich P8920
Critical Commercial Assays
Prime Flow RNA assay ThermoFisher 88-18005-210
Prime Flow IFNb1 ThermoFisher PF210 (VB10-3282108-PF)
Mouse IFN-beta ELISA PBL Assay Science 42410-1
Luciferase 1000 assay system Promega E4550
NE-PER Nuclear and cytoplasmic Extraction
Reagents
ThermoFisher 78833
AccuClear Nano dsDNA Assay kit Molecular Devices R3650A
LEGENDplex Mouse Inflammation Panel BioLegend 740150
Experimental Models: Cell Lines
4T07 Gerhard Christofori, Basel, Switzerland N/A
4T1 Burkhard Becher, Zurich, Switzerland N/A
B16BL6 Lubor Borsig, Zurich, Switzerland N/A
B16F10 ATCC CRL-6475
CMS5a Hiroyoshi Nishikawa, Osaka, Japan N/A
CT26 ATCC CRL-2638
LL171 Roman Spo¨rri, ETHZ, Switzerland N/A
LLC ATCC CRL-1642
MC38 Mark Smyth, Brisbane, Australia N/A
MC57 Rolf Zinkernagel, Zurich, Switzerland N/A
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and fulfilled by the Lead Contact, Dr. Maries van
den Broek (vandenbroek@immunology.uzh.ch).
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse strains
BALB/cRj1 and C57BL/6NRj mice were purchased from Janvier and cGAS-deficient (cGAS/, B6(C)-Cgastm1d(EUCOMM)Hmgu/J) mice
were purchased from Jackson Laboratory. NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were originally obtained from the Jackson
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
RN5 Emanuela Felley-Bosco, Zurich,
Switzerland
N/A
CT26DMb21d1 This paper N/A
CT26DTmem173 This paper N/A
CT26DGja1 This paper N/A
CT26Ctrl This paper N/A
LLCMb21d1 This paper N/A
X63-mGM-CSF Manfred Kopf, Zurich, Switzerland N/A
Experimental Models: Organisms/Strains
BALB/cRj1 Janvier N/A
C57BL/6NRj Janvier N/A
B6(C)-Cgastm1d(EUCOMM)Hmgu/J The Jackson Laboratory 026554
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ The Jackson Laboratory 013062
C57BL/6J-Tmem173Gt/J The Jackson Laboratory 017537
B6.129S2-Ifnar1tm1Agt/Mmjax The Jackson Laboratory 32045-JAX
Oligonucleotides
Primers for CRISPR/Cas9 genomic editing,
see Table S1
This paper N/A
Recombinant DNA
pSpCas9(BB)-2A-GFP Addgene PX458; 48138
pLenti-EF1a-Flag-mm-cGas Winfried Barchet, Bonn, Germany N/A
pMD2.G Addgene 12259
pCMV-dR8.91 Christian M€unz, Zurich, Switzerland N/A
Software and Algorithms
Prism GraphPad Prism software Version 7.0
FlowJo Tree Star software Version 10.1
inForm PerkinElmer CLS1355781
ImageJ Fiji N/A
Other
Irradiation unit RADSOURCE RS2000
FastPrep tissue homogenizer MPBiomedicals N/A
Zirconium beads Precellys BER103BK
Multispectral microscopy system Vectra 3.0 PerkinElmer N/A
SpectraMax i3 Molecular Devices N/A
DM6 B fluorescent microscope Leica Biosystems N/A
IX83 microscope Olympus N/A
Scan R imaging platform Olympus N/A
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Laboratory and provided by Christian M€unz, University of Zurich, Switzerland. Femora and tibiae from STING-deficient (C57BL/6J-
Tmem173Gt/J; Tmem173Gt) mice were provided by Winfried Barchet, University of Bonn, Germany. All mice were kept and bred un-
der pathogen-free conditions at the Laboratory Animal Services Center at the University of Zurich. All experiments were performed
with 8-12-weeks-old female mice, unless stated otherwise. All animal experiments were approved by the Cantonal Veterinary Office
Zurich under the license number 084/2015 and 140/2018 and performed according to cantonal and federal regulations.
Cell lines
CT26, LLC, 4T1, B16F10, B16BL6, MC38, MC57, CMS5a and 4T07 provided by were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, GIBCO) supplemented with 5% fetal calf serum (FCS, Thermo Fisher Scientific), 30 U/ml Penicillin, 30 mg/ml
Streptomycin (antibiotics, Thermo Fisher Scientific) and 2 mM L-Glutamine (Thermo Fisher Scientific). RN5 cells were cultured in
DMEM/F-12 (1:1) medium (Thermo Fisher Scientific) supplemented with 15% FCS, 0.1 mM 2-mercaptoethanol (Sigma Aldrich),
1% MEM non-essential amino acids (Thermo Fisher Scientific) and 100 mM sodium pyruvate (Thermo Fisher Scientific) and antibi-
otics. LL171 (Uze´ et al., 1994) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (GIBCO) supplemented with
10% FCS, L-Glutamine and antibiotics. CT26 Mb21d1-, Tmem173- or Gja1-deficient cells, and LLC Mb21d1-overexpressing cells
were generated and cultured as described above.
All cell lines were tested negative for a number of pathogens including Mycoplasma ssp. by PCR.
Colorectal adenocarcinoma paraffin sections
Tumor tissues from patients with colorectal adenocarcinoma of the proximal colon were collected at the Triemli Hospital Zurich,
Switzerland. Donors provided written, informed consent to tissue collection, analysis and data publication. Law abidance was re-
viewed and approved by the ethics commission of the Canton Zurich (KEK-ZH-2015-0068 and KEK-ZH-2013-0584). Samples
were numerically coded to protect donors’ rights to confidentiality and privacy. The microsatellite-instability (MSI) status was deter-
mined by immunohistochemical detection of MLH1 and MLH2. We analyzed 25 patients with MS-stable disease.
METHOD DETAILS
Modification of cell lines
Mb21d1 (cGAS), Tmem173 (STING) or Gja1 (CX43) genes were targeted in CT26 cells using CRISPR/Cas9. Per gene, three guide-
RNAs (gRNAs) were designed (Table S1), of which two were paired per transfection. gRNAs were cloned into the pSpCas9(BB)-2A-
GFP vector. CT26 cells were transfected with polyethyleneimine (PEI) and 2000 ng of two PX458-gRNA expression plasmids
per target gene. GFP+ cells were FACS-sorted using a FACSARIA III (BD Biosciences) and cloned by limiting dilution. Absence of
target gene was confirmed in cGAS-deficient CT26 (CT26DMb21d1), STING-deficient CT26 (CT26DTmem173) and CX43-deficient
CT26 (CT26DGja1) by Western Blot. In order to avoid potential single-clone-dependent artifacts, oligoclonal cell lines were generated
as follows. Five clones with determined deficiency of target gene were mixed in equal parts and used for experiments. The control
CT26 cell line (CT26ctrl) was generated as described above using the empty PX458 vector.
To overexpress cGAS, we used the lentiviral plasmid pLenti-EF1a-Flag-mm-cGAS. Lentiviral particles were generated using a sec-
ond-generation lentiviral packaging system consisting of pMD2.G and pCMV-dR8.91. LLC cells were transduced and subsequently
cultured in DMEM supplemented with 2 mg/ml puromycin (Invitrogen, #A11138-03) to select transduced cells. cGAS overexpression
was confirmed by Western Blot.
Measurement of cGAS and STING in tumor cell lines
Tumor cells (1.5x106) were seeded in T175 flasks, cultured for 24 h and expression of cGAS and STING was quantified by Western
Blot.
To assess the function of cGAS and STING, 3x105 tumor cells/well were seeded in 24-well plates. Tumor cells were transfected
with 1 mg genomic DNA extracted from CT26 cells using PEI. Cells were incubated overnight at 37C and type I IFNs were quantified
in the supernatant using the LL171 (Uze´ et al., 1994) reporter cell line.
Co-culture experiments
Bone marrow-derived dendritic cells (BMDCs) were generated as described (Inaba et al., 1992). Briefly, bone marrow cells were
cultured in RPMI 1640 medium containing 10% supernatant from X63-mGM-CSF cells for 7-9 days. At least 85% of the resulting
cells expressed CD11c and MHC class II as determined by flow cytometry (not shown). Hundred-fifty-thousand tumor cells and
0.5x106 BMDCs were co-cultured in a well of a 24-well plate. After 24h, supernatant was collected and type I IFNs were quantified
using the reporter cell line LL171. Alternatively, IFNb was quantified by ELISA.
In vivo tumor experiments and treatments
Tumor cells were suspended at 2x106/ml in a 2:1 mix of PBS:Matrigel. Hundred ml of this suspension were injected subcutaneously
(s.c.) into the right flank ofmice. Tumor sizewasmeasured in two dimensions (length andwidth) every 2-4 days starting on day 7 using
a caliper. Immediately before start of interventions, mice were assigned to different experimental groups in suchway that the average
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and variance of tumor size was similar for each group. Radiotherapy was applied locally on the tumor as a single dose of 13 20 Gy
with 1.6 Gy/min on day 13 (Surace et al., 2015). Cisplatin (Sandoz) was injected i.p. at 3 mg/kg on day 8 and 13. Control mice were
injected with 150 mL of 0.9% NaCl. For immune checkpoint inhibition, anti-PD1 (RMP1-14) and anti-CTLA4 (9H10) monoclonal
antibodies were injected i.p. at 250 mg per dose on day 7 and 12. Control mice were injected with 200 mL PBS. CD8+ T cells were
depleted on day 9 by i.p. injection of 250 mg of a CD8-depleting antibody (YTS169.4). Control mice were injected with 100 mL
PBS. For survival studies, mice were euthanized when the tumor reached a size of 225 mm2.
Flow cytometry
Excised tumors were collected in RPMI supplemented with 10% FCS and cut into small pieces. Tumor pieces were digested with
1 mg/ml collagenase IV (Bioconcept) at 37C on a rotating device. After 45 min, 2.6 mg/ml DNaseI (ThermoFisher Scientific) was
added and digestion continued for additional 15 min at 37C. Cells were washed with 0.01 M EDTA in PBS by centrifugation at
350 g for 5 min. Red blood cells were lysed using RBC lysis buffer (17 mM Tris pH 7.2, 144 mM NH4Cl) for 2 min. Cells were washed
with PBS and filtered through a 70 mm filter to remove debris. Single cells were stained according to standard protocols. Briefly, cells
were surface-stained in 50 mL antibody-mix in PBS. Dead cells were excluded using fixable viability stain according to the manufac-
turer’s instructions. For intracellular cytokine staining, cells were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA)
plus 500 ng/ml ionomycin or with AH-1 peptide (Huang et al., 1996) (SPSYVYHQF, the H-2Ld-restricted epitope derived from endog-
enous retroviral gp70, which is expressed in CT26, 106 M) for 1 h at 37C. Subsequently, brefeldin A (10 mg/ml) was added and cells
were incubated for additional 3 h. Cells were stained for surface molecules as described above, washed with PBS, and fixed for
30min on ice using IC Fixation Buffer from Foxp3/Transcription Factor Staining Buffer Set. Subsequently, cells were stained for intra-
cellular IFNg in 1X permeabilization buffer from the Foxp3/Transcription Factor Staining Buffer Set overnight at 4C. After washing
with 1X permeabilization buffer, samples were suspended in FACS buffer (PBS, 20 mM EDTA pH 8.0, 2% FCS) and acquired using
a CyAn ADP9 flow cytometer (Beckman Coulter) or FACS LSRII Fortessa (BD Biosciences).
Due to lack of suitable antibodies for intracellular staining of type I IFN, we detected Ifnb1 transcripts in single cells by flow cytom-
etry using the PrimeFlow RNA Assay according to manufacturer’s protocol. Briefly, single-cell suspensions were surface-stained as
described above. Fixation and permeabilization was performed according to manufacturer’s instructions. For mRNA detection, in
situ hybridization with type I Alexa Fluor 568-labeled Ifnb1 probe was performed for 2 h at 40C. The signal was amplified by incu-
bating samples for 2 h in PreAmplification reagent at 40C and additional 2 h at 40C in Amplification reagent. Samples were incu-
bated with label probes at 40C for 1 h, washed and acquired on a FACS LSRII Fortessa (BD Biosciences).
For quantitative analysis, CountBright absolute counting beadswere used (ThermoFisher Scientific). In all staining, dead cells were
excluded using Live/Dead fixable staining reagents (Invitrogen), and doublets were excluded by FSC-A versus FSC-H gating. Sam-
ples were analyzed using FlowJo v10 software (Tree Star Inc.). Analysis was performed on single, live cells.
Western blotting
To extract proteins, cells were suspended in RIPA buffer (ThermoFisher) supplemented with protease inhibitor (cOmplete, Mini Pro-
tease Inhibitor Cocktail, Roche) and subjected to two freeze-thaw cycles. The protein concentration was determined using the DC
Protein Assay (Bio-Rad). For quantification of cGAS and Connexin 43 (CX43, GJA1), a total of 20 mg protein was loaded and for the
determination of STING, 100 mg were loaded per lane of a 10% SDS-PAGE gel. Proteins were transferred onto a nitrocellulose mem-
brane (GEHealthcare Life science) with 350mA for 2 h at 4C. Themembranewas blocked in 5%non-fat milk powder in Tris-buffered
saline containing 0.05% Tween-20 (TBS-T) for 1 h at room temperature (RT) or overnight at 4C. Membranes were stained with the
primary antibodies against cGAS (1:1’000), STING (1:1’000), CX43 (1:1’000), a-TUBULIN (1:50000) or b-ACTIN (1:50000). Membranes
were incubated for 1 h at RT or overnight at 4C with antibodies diluted in 5% non-fat milk powder in TBS-T. Membranes were
washed three times for 10 min in TBS-T and incubated in with the secondary antibody: HRP-goat-anti-mouse IgG (1:10’000) or
HRP-goat-anti-rabbit IgG (1:10’000) in 5% non-fat milk powder in TBS-T for 1 h at RT. Membranes were washed three times for
10 min in TBS-T and chemiluminescent reaction was started using the WesternBright ECL kit (Advansta). Protein bands were de-
tected using a Fusion Solo S imager (Vilber). The Precision Plus Protein Dual Color Standard (Bio-Rad) was used to assess molecular
weight of protein bands. Relative quantification of cGAS/b-ACTIN and STING/a-TUBULIN ratio was performed using ImageJ
software.
Quantification of type I IFN
Type I IFNs were quantified using the reporter cell line LL171. Briefly, 3.5x104 LL171 cells were seeded per well in 96-well flat-bottom
plates and incubated with samples for 24 h at 37C in a CO2-incubator. Reporter cells were lysed using the Luciferase Cell Culture
Lysis 5X Reagent and transferred to a white 96-well LUMITRAC plate (Greiner Bio-One GmbH). Luciferase activity was measured
using the Luciferase Assay System in a TECAN plate reader (Tecan). Standard curves were prepared using serial dilutions of recom-
binant murine IFNb ranging from 0 to 1’000 pg/ml.
Quantification of cytoplasmic DNA
Tumor cells were seeded at 1x106 cells/well in a 6-well plate and exposed to DNA-damaging treatments. Specifically, cells were
irradiated with 8 or 20 Gy using a RS2000 (Radsource) irradiation machine at 6.7 Gy/min or treated with 15 mM Cisplatin (Sandoz).
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Cytoplasmic dsDNA was measured in live cells 24 h later. As a control, 1x106 fresh splenocytes were used. The cytoplasmic fraction
was extracted using the NE-PER Nuclear and Cytoplasmic Extraction Reagents. Cytoplasmic dsDNA was quantified using the Ac-
cuClear Nano dsDNA Assay Kit and a SpectraMax i3 (Molecular Devices) microplate reader as described (Vanpouille-Box et al.,
2017).
Quantification of cytokines in tumor lysates
Pieces of excised tumors were snap-frozen in liquid nitrogen and stored at 80C. To prepare a lysate, 2x weight in volume of PBS
supplemented with protease inhibitor was added to frozen tumor pieces. Zirconium oxide beads were added, and samples were ho-
mogenized for 30 s at 5 m2/s2 using a FastPrep instrument using. Samples were centrifuged at 4C at 14’000 g for 15 min. The su-
pernatant was collected on ice and immediately used. Total protein concentration was measured using DC Protein Assay (Bio-Rad).
Cytokines were quantified in lysates using the LEGENDplex Mouse Inflammation Panel according to manufacturer’s instructions.
Samples were acquired on CyAn ADP9 flow cytometer (Beckman Coulter). IFNbwas quantified by ELISA and read on a SpectraMax
i3 (Molecular Devices) plate reader.
Four-color immunofluorescence
For antigen-retrieval, slides were heated for 2 h at 55C and incubated in Trilogy pretreatment solution (CellMarque) in a pres-
sure cooker for 15 min. After cooling for 15 min, slides were washed with milli-Q to remove remaining paraffin and treated with
3% H2O2 in H2O for 15 min. Slides were washed with milli-Q water and incubated with 4% BSA/0.01% Triton X-100 in PBS for
15 min at 37C to prevent unspecific binding of antibodies. Subsequently, slides were incubated overnight at 4C or 3 h at RT
with a primary antibody diluted in 1% BSA/0.01% Triton X-100 in PBS. Following primary antibodies were used: anti-cGAS
(1:500), anti-Pan-Cytokeratin (1:2000) and anti-CD8 (1:1000). After incubation, slides were washed 3 times for 5 min with
0.01% Triton X-100 in PBS and incubated for 1 h at RT with following HRP-conjugated secondary antibodies: Donkey-anti-
rabbit IgG (1:1’000) and donkey-anti-mouse IgG (1:1’000), diluted in 1% BSA in 0.01% Triton X-100 in PBS. The signal was
amplified using 1:100-diluted fluorophore-conjugated tyramides Opal 520, Opal 540 and Opal 690 in amplification buffer
(PerkinElmer) for 10 min at RT. Slides were washed subsequently and boiled for 12 min in 10 mM citric acid pH 6.0 to strip
the bound antibodies. Blocking and incubation with the next primary and secondary antibody, tyramide amplification and strip-
ping was repeated for different targets that were consecutively detected. Finally, slides were washed, incubated with 0.5 mg/ml
40,6 diamidine-2-phenylindole (DAPI; Invitrogen) for 5 min, washed again and mounted with ProlongDiamond medium
(Invitrogen).
Calcein AM transfer assay
Tumor cells were washed twice with PBS and labeled with Calcein AM dye (5 mg/ml in PBS) at 37C for 30 min in the dark. Cells were
washed twice with PBS and 0.5x106 cells were plated in complete RPMI in a well of a 12-well plate. Five-hundred-thousand BMDCs
were added to the tumor cells and incubated at 37C for 6 h. Cells were collected, washed with PBS and surface-stained with fluo-
rescently-labeled antibodies. After washingwith PBS, samples were acquired using aCyAn ADP9 flow cytometer (BeckmanCoulter).
Calcein AM was detected in the FITC-channel.
Quantification of gamma-H2AX
Four-chambered culture slides (BD Falcon) were treated with poly-L-lysine for 10 min and dried for 2 h at RT. Seventy-five thousand
CT26ctrl andCT26DMb21d1were grown per chamber overnight. Cells were left untreated, irradiated with 1Gy or 5 Gy and incubated for
1 h. Slides were briefly washed with PBS and incubated with the pre-extraction solution (25 mM HEPES pH 7.7, 50 mM NaCl, 1 mM
EDTA, 3 mM MgCl2, 300 mM sucrose, 0.5% Triton X-100) for 5 min on ice. After washing with PBS, cells were fixed with 4% para-
formaldehyde in PBS for 15 min at RT. To prevent unspecific binding of antibodies, slides were incubated with 1% BSA in PBS for
15 min. Slides were incubated with anti-gamma-H2AX (1:200, Millipore) in 1% BSA in PBS for 90 min at RT. Slides were washed and
incubated with the AlexaFluor568-coupled secondary antibody goat anti-mouse IgG (1:400, Life Technologies) in 1% BSA in PBS in
the dark for 30 min at RT. Slides were washed three times with PBS and stained with 0.5 mg/ml 40,6 diamidine-2-phenylindole (DAPI;
Invitrogen) in deionized H2O for 5 min, washed again and mounted with FluoroMount medium (Invitrogen). Immunofluorescent im-
ages were captured on a DM6B fluorescent microscope (Leica Biosystems) using an oil-immersion objective (63x/1.4 NA). The auto-
mated image acquisition was performed on an IX83 microscope (Olympus) equipped with ScanR imaging platform and 40x/0.9 NA
objective. Nuclei were identified based onDAPI signal, and the intensity of gamma-H2AX for each nuclear object were analyzed using
the Analysis ScanR software. At least 500 nuclei were analyzed per sample.
Colony-forming assay
The colony-forming assay was performed according to the description in Franken et al. (2006). Briefly, 10, 50 and 100 CT26ctrl and
CT26DMb21d1were seeded in one well of a 6-well plate in duplicates and incubated for 4 h at 37C. Cells were left untreated, irradiated
with 2, 4, 5, 6 or 9 Gy or treated with Cisplatin (Sandoz) at concentrations of 1, 3, 15 or 30 mM. Cells were incubated for 6 days to form
colonies. Colonies were washed with PBS, fixed and stained with 6% glutaraldehyde, 0.5% crystal violet in H20 for 30 min. Fixation-
staining solution was removed and wells were rinsed several times carefully with tap water. Plates were dried at RT and colonies
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counted by eye. For the untreated control, the plating efficiency was calculated as followed: [# coloniesO # cells seeded] x 100%.
For each treatment condition, the surviving fraction was calculated as follows: # coloniesO [# cells seeded x plating efficiency].
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification of immunofluorescence data
Stained slides were scanned using the automated multispectral microscopy system Vectra 3.0 (PerkinElmer). Six to 8 representative
areas of tumor tissue were imaged at 200-fold magnification. Inform software (PerkinElmer) was used for spectral unmixing of
individual fluorophores and autofluorescence, and to apply cell segmentation and quantification algorithm on the slide as described
(Silin‚ a et al., 2018a, 2018b). Samples were excluded where the area was damaged, or the algorithm was not identifying properly.
Statistical analysis
Group sizes, number of replications, and explanation of the mean and error bars are provided in the figure legends. Statistical tests
were performedwith GraphPad Prism 7.0 (GraphPad Software). For comparison of two experimental groups, the unpaired two-tailed
Student’s t test was used, unless stated otherwise. When more than two groups were compared, the one-way ANOVA with Tukey’s
multiple comparison correction was used. Survival data were analyzed with a Log-rank (Mantel-Cox) test. *p < 0.05, **p < 0.01, ***p <
0.005, ****p < 0.001. Data are shown as mean ± SD unless specified otherwise.
DATA AND CODE AVAILABILITY
This study did not generate any unique datasets or code.
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